

Although PMPRB states that it is proposing to adopt a "status quo " approach to carrying out its regulatory mandate, it then states that "he PMPRB will not conduct a price review of any new patented medicines or open any investigations in respect of them until the new guidelines come into effect." That is not "status quo." It is a suspension of operations. PMPRB should continue to use the old basket until new Guidelines are in place. These should have been developed in advance in any case as PMPRB knew that the basket was going to change.